Sellas Life Sciences Group Gets FDA Orphan Drug Designation to Treat Type of Leukemia
Provided by
Dow Jones
By Sabela Ojea
Sellas Life Sciences Group said it received an orphan drug designation from the U.S. Food and Drug Administration to treat acute myeloid leukemia.
The clinical biopharmaceutical company on Tuesday said its SLS009 inhibator, aimed at being administered twice weekly, has shown a favorable safety profile, strong initial efficacy signals and evidence of antitumor activity.
Orphan drug designations are granted to drugs or biologics used for the treatment, prevention or diagnosis of a rare disease that affects less than 200,000 people in the U.S.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
October 10, 2023 16:47 ET (20:47 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Berkshire Hathaway Earnings: Strong Insurance Results Continue to Lift Revenue and Profitability
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom